All In Biotech

Drug Trial Radar · NCT06276556

Extension Study of ABP-671 in Participants With Gout

A Multicenter, Double-blind, Phase 2b/3 Extension Study to Assess the Safety and Efficacy of ABP-671 in Participants With Gout Who Completed the Double-blind Treatment Period in Study ABP-671-301

Last checked: Nov 19, 2026Latest source record: Jul 16, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

43

Actual

Start

Apr 22, 2024

Primary completion

Sep 5, 2024

Study completion Sep 5, 2024

Sponsor

Lead sponsor
Atom Therapeutics Co., LtdIndustry
Sponsor type
Industry
First posted
Feb 26, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 19 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objectives of this study are to assess the safety, tolerability, and efficacy of ABP-671 in lowering serum uric acid (sUA) in participants with gout who roll over from Study ABP-671-301 after they complete the double-blind 28-week Treatment Period of Part 1 (Phase 2b) or Part 2 (Phase 3).

Conditions

  • Gout

Interventions

  • ABP-671Drug

    Participants who were randomized to any of the ABP-671 treatment groups in Part 1 or Part 2 of Study ABP-671-301 will continue to receive the same dose level and dosing regimen during the Treatment Period of this Extension Study. Participants who were randomized to receive placebo in Part 1 or Part 2 of Study ABP-671-301 will receive ABP-671 during the Treatment Period of the Extension Study.

  • AllopurinolDrug

    Participants who were randomized to receive allopurinol in Part 1 of Study ABP-671-301 will continue to receive allopurinol during the Treatment Period of the Extension Study.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of participants who achieve serum uric acid (sUA) levels <6.0 mg/dL (<0.360 mmol/L)Time frame: Week 26
  2. Incidence of treatment-emergent adverse events (Safety and Tolerability)Time frame: Week 26

Locations

54 sites in 5 countries. Site status is shown where the registry gives one.

  • Alliance for Multispecialty Research

    Tempe, Arizona

  • Tucson Neuroscience Research, LLC

    Tucson, Arizona

  • Anaheim Clinical Trials (Cenexel ACT)

    Anaheim, California

  • Center for Clinical Trials of Sacramento

    Sacramento, California

  • Access Research Institute

    Brooksville, Florida

  • Nature Coast Clinical Reasearch

    Crystal River, Florida

  • JY Research Institute Inc.

    Cutler Bay, Florida

  • Accel Clinical Research Site

    DeLand, Florida

  • Jacksonville Center for Clinical Research

    Jacksonville, Florida

  • A & D Doctor Center

    Miami, Florida

  • Bioclinical Research Alliance

    Miami, Florida

  • Cordova Research Institute

    Miami, Florida

  • Century Research LLC

    Miami, Florida

  • ITB Research

    Miami, Florida

  • Combined Research Orlando Phase I-IV

    Orlando, Florida

  • New Horizons Research

    Palmetto Bay, Florida

  • Advanced Clinical Research of Atlanta

    Atlanta, Georgia

  • Centricity Research

    Columbus, Georgia

  • Alliance for Multispecialty Research, LLC.

    Newton, Kansas

  • DelRicht Research

    New Orleans, Louisiana

  • AMR

    New Orleans, Louisiana

  • Annapolis Internal Medicine/CCT Research

    Annapolis, Maryland

  • DelRicht Research of Gulfport

    Gulfport, Mississippi

  • Quality Clinical Research, Inc

    Omaha, Nebraska

  • Santa Rosa Medical Center

    Las Vegas, Nevada

  • Inspire Santa Fe Medical Group

    Santa Fe, New Mexico

  • OnSite Clinical Solutions

    Salisbury, North Carolina

  • Altoona Center for Clinical Research

    Duncansville, Pennsylvania

  • ClinSearch

    Chattanooga, Tennessee

  • Medical Care/CCT

    Elizabethton, Tennessee

  • PanAmerican Clinical Research, LLC

    Brownsville, Texas

  • Quality Research Inc.

    San Antonio, Texas

  • Worldwide Clinical Trials

    San Antonio, Texas

  • Paratus Clinical Research Western Sydney

    Blacktown, New South Wales, Australia

  • Emeritus Research Sydney

    Botany, New South Wales, Australia

  • Paratus Clinical Research Central Coast

    Kanwal, New South Wales, Australia

  • A R Houston Medical Pty Ltd

    Kippa-Ring, Queensland, Australia

  • Emeritus Research Melbourne

    Camberwell, Victoria, Australia

  • Austin Health - Repatriation Hospital

    Heidelberg, Victoria, Australia

  • New Hospitals

    Tbilisi, Georgia

Showing 40 of 54 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.